Pharmacology

INTERVIEW

Dimas Covas: The trajectory of Butantan

The hematologist from USP readies the São Paulo institute to fight the pandemic and has plans to transform it into one of the world’s top producers of vaccines and serums

By and

COVID-19

vaccine. Now what?

The introduction of vaccines in the battle against the COVID-19 pandemic raises new challenges

By

COVID-19

Yes to the vaccine

On January 18, FAPESP started the #vacinasim (“yesvaccine”) social media campaign to reinforce public confidence in their safety and effectiveness

By

COVID-19

The era of genetic vaccines

The vaccines from BioNTech/Pfizer and Moderna result from historical investments in messenger RNA technology leading to the creation of new products

By

COVID-19

Distribution challenges

Governments need to work with pharmaceutical and logistics companies to overcome obstacles to start the SARS-CoV-2 immunization campaign

By

COVID-19

Butantan develops serum for the novel coronavirus

The Butantan Institute has completed development of a serum to combat SARS-CoV-2

By

COVID-19

Unequal access

Even before efficacy data for the vaccine candidates was released, it was clear that there will not be enough supply to immunize the entire global population before the end of next year

By

COVID-19

Australia gives up on vaccine candidate

A vaccine being developed by the University of Queensland and biotechnology company CSL, both from Australia, is the first of more than 200 candidates to be discarded

By

COVID-19

Vaccines and sharks

A compound extracted from the livers of sharks is used in five coronavirus vaccine candidates

By

FIOCRUZ – 120 YEARS

A continuum of challenges

From the bubonic plague to Zika fever, the Oswaldo Cruz Foundation’s 120-year history has been punctuated by a succession of novel diseases and related discoveries

By

FIOCRUZ – 120 YEARS

No rest on the anniversary

FIOCRUZ celebrates 120 years of public health literature, research, assistance, and teaching

By

Cover

Vaccines edge closer

Less than a year after first cases of COVID-19 were confirmed, vaccine candidates in the final stages of development offer promising results

By

COVID-19

Nasal spray prevents infection in ferrets

A nasal spray tested on ferrets prevented absorption of SARS-CoV-2 and for a period of 24 hours, prevented them from becoming infected with the novel coronavirus when exposed to animals known to be affected by the pathogen

By

COVID-19

Stuttering progress

Advanced testing of COVID-19 vaccines continues at an accelerated pace, despite occasional interruptions caused by safety concerns

By

Obituary

The pharmacy of plants

Elisaldo Carlini, a pioneer in the study of medicinal plants and cannabis compounds, dies at 90 years of age

By

Innovation

A place in the sun

A thriving generics industry and government funding have helped to boost research and development spending among Brazilian pharmaceutical companies, study shows

By

COVID-19

Study determines Chinese vaccine is safe

CoronaVac is safe and has no serious side effects

By

COVID-19

Antibody treatment reduces time spent in hospital

American pharmaceutical company Eli Lilly presented the initial results of a clinical trial that used monoclonal antibodies in patients infected with the novel coronavirus

By

Pharmacology

Schistosomiasis medicine

The US FDA has granted orphan drug status to the immunomodulator P-MAPA for use against schistosomiasis

By

COVID-19

Intranasal coronavirus vaccine

Two international studies have suggested that COVID-19 aerosol vaccine candidates, administered intranasally, offer protection against SARS-CoV-2 infection in animals

By

COVID-19

Vaccine tests advance

One of the best-known COVID-19 vaccine candidates achieved good results in the first phase of clinical trials

By

Pharmacology

Lasting action against HIV

Researchers at American pharmaceutical company Gilead Sciences have published the results of clinical trials of a new long-acting antiretroviral against HIV

By

Data

At least 125 COVID-19 vaccines are in development, with 10 already undergoing clinical trials

Vaccines in the clinical trials phase worldwide and in development in Brazil (as of May 27, 2020)

By

Cover

Progress toward dengue vaccine

A formulation developed by the Butantan Institute has shown protective effects in the second phase of testing

By

Cover

The antivirus arsenal

The search for an effective treatment for COVID-19 includes testing drugs already used against other diseases and even plasma

By

Pharmacology

Monkeys are the best animal model

Monkeys appear to be the best animals for testing SARS-CoV-2 vaccines and drugs

By

Pharmacology

Medicines from Cannabis

Based on its proven efficacy for epilepsy, cannabidiol has become the target of intensive research

By

Video

Techniques in the search for a vaccine against Covid-19

Teams from several countries head projects seeking to produce imunizing agents in a short time

By

Interview

João Batista Calixto: The voice of Brazilian pharmaceuticals

The pharmacologist from Minas Gerais has dedicated his life to developing new drugs

By

Public health

The challenge of diagnosing Zika

There is no scientific consensus that any of the 48 approved laboratory tests can differentiate between Zika and the dengue virus

By